ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,469.30
0.39%
Dow Jones
39,112.16
-0.76%
US Dollar vs MXN
18.1479
0.12%
Brent Oil
84.965
0.93%
Bitcoin
61,276.11
-0.87%
Registration Strip Icon for monitor Monitoree múltiples cotizaciones en tiempo real de los principales intercambios, como la Bolsa de Valores de Londres, NASDAQ, NYSE, AMEX, Bovespa y más.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. argenx SE (ARGX)

  7. argenx SE (ARGX) Noticias

ARGX

argenx (ARGX)

argenx SE
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NASDAQ:ARGX
FechaHoraFuenteTítuloSímboloCompañía
25/06/202415:30GlobeNewswire Inc.argenx Highlights Breadth of Autoimmune Pipeline with New Multifocal Motor Neuropathy Data at 2024 Peripheral Nerve Society Annual MeetingNASDAQ:ARGXargenx SE
21/06/202415:50GlobeNewswire Inc.argenx Announces FDA Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating PolyneuropathyNASDAQ:ARGXargenx SE
17/06/202405:05Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:ARGXargenx SE
17/06/202400:00GlobeNewswire Inc.argenx to unveil its ‘Vision 2030: Taking Breakthrough Science to 50,000 Patients’ during its Upcoming R&D Day on July 16, 2024NASDAQ:ARGXargenx SE
04/06/202400:00GlobeNewswire Inc.argenx to Present at Goldman Sachs 45th Annual Global Healthcare ConferenceNASDAQ:ARGXargenx SE
09/05/202400:00GlobeNewswire Inc.argenx Reports First Quarter 2024 Financial Results and Provides Business UpdateNASDAQ:ARGXargenx SE
07/05/202416:30GlobeNewswire Inc.argenx announces results of Annual General Meeting of ShareholdersNASDAQ:ARGXargenx SE
07/05/202400:00GlobeNewswire Inc.argenx to Present at BofA Securities 2024 Health Care ConferenceNASDAQ:ARGXargenx SE
02/05/202400:00GlobeNewswire Inc.argenx to Report First Quarter 2024 Financial Results and Business Update on May 9, 2024NASDAQ:ARGXargenx SE
16/04/202400:00GlobeNewswire Inc.argenx Data Highlight Evidence that VYVGART and VYVGART Hytrulo Drive Transformative Outcomes for Patients with Debilitating Autoimmune DiseaseNASDAQ:ARGXargenx SE
27/03/202401:00GlobeNewswire Inc.argenx Advances Clinical Development of Efgartigimod in Primary Sjogren’s DiseaseNASDAQ:ARGXargenx SE
26/03/202415:00GlobeNewswire Inc.argenx Announces Annual General Meeting of Shareholders on May 7, 2024NASDAQ:ARGXargenx SE
26/03/202401:00GlobeNewswire Inc.argenx Announces Approval of VYVGART (efgartigimod alfa) in Japan for Adults with Primary Immune ThrombocytopeniaNASDAQ:ARGXargenx SE
07/03/202415:01GlobeNewswire Inc.argenx Delivers on Promise to Transform Patient Expectations in Autoimmunity at American Academy of Neurology 2024 Annual MeetingNASDAQ:ARGXargenx SE
29/02/202400:00GlobeNewswire Inc.argenx Reports Full Year 2023 Financial Results and Provides Fourth Quarter Business UpdateNASDAQ:ARGXargenx SE
26/02/202400:00GlobeNewswire Inc.argenx to Present at Upcoming Investor ConferencesNASDAQ:ARGXargenx SE
22/02/202400:00GlobeNewswire Inc.argenx to Report Full Year 2023 Financial Results and Fourth Quarter Business Update on February 29, 2024NASDAQ:ARGXargenx SE
20/02/202400:00GlobeNewswire Inc.argenx Announces FDA Acceptance of Supplemental Biologics License Application with Priority Review for VYVGART Hytrulo in Chronic Inflammatory Demyelinating PolyneuropathyNASDAQ:ARGXargenx SE
18/01/202400:00GlobeNewswire Inc.argenx Announces Approval of VYVDURA® (efgartigimod alfa and hyaluronidase-qvfc) Injection for Subcutaneous Use in Japan for Generalized Myasthenia GravisNASDAQ:ARGXargenx SE
08/01/202400:00GlobeNewswire Inc.argenx Highlights 2024 Strategic PrioritiesNASDAQ:ARGXargenx SE
02/01/202400:00GlobeNewswire Inc.argenx to Present at 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:ARGXargenx SE
20/12/202311:37Dow Jones NewsArgenx Down Nearly 26%, on Pace for Record Percent Decrease -- Data TalkNASDAQ:ARGXargenx SE
20/12/202300:00GlobeNewswire Inc.argenx Reports Topline Results from ADDRESS Study of Efgartigimod SC in PemphigusNASDAQ:ARGXargenx SE
28/11/202310:16Dow Jones NewsArgenx Down Over 10%, On Track for Largest Percent Decrease Since May 2022 -- Data TalkNASDAQ:ARGXargenx SE
28/11/202306:03Dow Jones NewsArgenx Shares Down After Vyvgart Study Misses Primary EndpointNASDAQ:ARGXargenx SE
28/11/202300:00GlobeNewswire Inc.argenx Reports Topline Results from ADVANCE-SC Study of VYVGART Hytrulo in Primary Immune ThrombocytopeniaNASDAQ:ARGXargenx SE
16/11/202306:40GlobeNewswire Inc.argenx Announces European Commission Approval of Subcutaneous VYVGART® (efgartigimod alfa) for Generalized Myasthenia GravisNASDAQ:ARGXargenx SE
01/11/202301:00GlobeNewswire Inc.argenx Highlights Data Evaluating VYVGART in Neuromuscular Autoimmune Disease at AANEM and MGFA Scientific SessionsNASDAQ:ARGXargenx SE
31/10/202301:00GlobeNewswire Inc.argenx Reports Third Quarter 2023 Financial Results and Provides Business UpdateNASDAQ:ARGXargenx SE
24/10/202300:00GlobeNewswire Inc.argenx to Report Third Quarter 2023 Financial Results and Business Update on October 31, 2023NASDAQ:ARGXargenx SE
 Showing the most relevant articles for your search:NASDAQ:ARGX

Su Consulta Reciente

EU
H380T
H380T
LSE
SK89
Int.fin. 28
TSX
CRON
Cronos
LSE
92YY
Shell Intl 39
BIT
UB7N6Z
Unicredit Bank
BIT
UC5GSX
Unicredit Bank
USOTC
KREVF
Keppel REIT (PK)
LSE
RT65
Newday Fmi 25 S
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

México
Empresa
Negocios
Popular
Obtener la aplicación
App Store
Google Play

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados